-
公开(公告)号：US20220370420A1
公开(公告)日：2022-11-24
申请号：US17204089
申请日：2021-03-17
Applicant: Genentech, Inc.
Inventor： Sushant Malhotra , Craig Stivala , BinQing Wei , Bryan K. Chan , Timothy Heffron , Michael Lainchbury , Andrew Madin , Terry Aaron Panchal , Eileen Mary Seward , Toby Blench , Matthew W. Cartwright , Elsa Amandine Dechaux , Richard Elliott , Emanuela Gancia
IPC: A61K31/437 , A61K45/06 , C07D471/10 , C07D491/20 , C07D519/00 , C07D487/20 , C07D471/20 , A61K31/5377 , A61K31/444 , A61K31/496 , A61K31/513 , A61K31/4985
Abstract: Spirocyclic 2,3-dihydro-7-azaindole compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the spirocyclic 2,3-dihydro-7-azaindole compounds.
-
公开(公告)号：US11034692B1
公开(公告)日：2021-06-15
申请号：US16542129
申请日：2019-08-15
Applicant: Genentech, Inc.
Inventor： Bryan Chan , Blake Daniels , Joy Drobnick , Lewis Gazzard , Timothy Heffron , Malcolm Huestis , Jun Liang , Sushant Malhotra , Rohan Mendonca , Naomi Rajapaksa , Michael Siu , Craig Stivala , John Tellis , Weiru Wang , BinQing Wei , Aihe Zhou , Matthew W. Cartwright , Emanuela Gancia , Graham Jones , Michael Lainchbury , Andrew Madin , Eileen Seward , David Favor , Kin Chiu Fong , Andrew Good , Yonghan Hu , Baihua Hu , Aijun Lu
IPC: C07D471/04 , A61K45/06 , A61P35/00 , A61K31/444 , A61K31/4375 , A61K31/506 , C07D519/00 , A61K31/4545 , A61K31/4725 , A61K31/5383 , A61K31/496 , A61K31/5377 , A61K31/5025 , A61K31/551 , A61K31/55
Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
-
公开(公告)号：US20210163417A1
公开(公告)日：2021-06-03
申请号：US16921297
申请日：2020-07-06
Applicant: Genentech, Inc.
Inventor： Bryan Chan , Joy Drobnick , Lewis Gazzard , Timothy Heffron , Jun Liang , Sushant Malhotra , Rohan Mendonca , Naomi Rajapaksa , Craig Stivala , John Tellis , Weiru Wang , BinQing Wei , Aihe Zhou , Matthew W. Cartwright , Michael Lainchbury , Emanuela Gancia , Eileen Seward , Andrew Madin , David Favor , Kin Chiu Fong , Yonghan Hu , Andrew Good
IPC: C07D217/22 , A61K31/549 , A61P35/00 , A61K45/06 , C07D401/04 , A61K31/4725 , A61K31/506 , A61K31/501 , C07D471/04 , C07D413/04 , C07D413/14 , A61K31/5377 , C07D417/04 , A61K31/4985 , C07D401/14 , C07D487/04 , A61K31/551 , C07D498/04 , A61K31/5383 , C07D405/14 , C07D519/00 , C07D498/14 , C07D513/04 , A61K31/554 , A61K31/55 , A61K31/472 , C07D409/14 , C07D491/04 , C07D487/14
Abstract: Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
-
公开(公告)号：US20180282328A1
公开(公告)日：2018-10-04
申请号：US15942321
申请日：2018-03-30
Applicant: Genentech, Inc.
Inventor： Bryan Chan , Blake Daniels , Joy Drobnick , Lewis Gazzard , Timothy Heffron , Malcolm Huestis , Jun Liang , Sushant Malhotra , Rohan Mendonca , Naomi Rajapaksa , Michael Siu , Craig Stivala , John Tellis , Weiru Wang , BinQing Wei , Aihe Zhou , Matthew W. Cartwright , Emanuela Gancia , Graham Jones , Michael Lainchbury , Andrew Madin , Eileen Seward , David Favor , Kin Chiu Fong , Andrew Good , Yonghan Hu , Baihua Hu , Aijun Lu
IPC: C07D471/04 , A61K45/06 , A61P35/00 , A61K31/444 , A61K31/4375 , A61K31/506 , C07D519/00 , A61K31/4545 , A61K31/4725 , A61K31/5383 , A61K31/496 , A61K31/5377 , A61K31/5025 , A61K31/551 , A61K31/55
CPC classification number: C07D471/04 , A61K31/4375 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/5025 , A61K31/506 , A61K31/5377 , A61K31/5383 , A61K31/55 , A61K31/551 , A61K45/06 , A61P35/00 , C07D519/00
Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
-
公开(公告)号：US20180282282A1
公开(公告)日：2018-10-04
申请号：US15942333
申请日：2018-03-30
Applicant: Genentech, Inc.
Inventor： Bryan Chan , Joy Drobnick , Lewis Gazzard , Timothy Heffron , Jun Liang , Sushant Malhotra , Rohan Mendonca , Naomi Rajapaksa , Craig Stivala , John Tellis , Weiru Wang , BinQing Wei , Aihe Zhou , Matthew W. Cartwright , Michael Lainchbury , Emanuela Gancia , Eileen Seward , Andrew Madin , David Favor , Kin Chiu Fong , Yonghan Hu , Andrew Good
IPC: C07D217/22 , A61K31/472 , A61P35/00 , A61K45/06 , C07D401/04 , A61K31/4725 , A61K31/506 , A61K31/501 , C07D471/04 , C07D413/04 , C07D413/14 , A61K31/5377 , C07D417/04 , A61K31/4985 , C07D401/14 , C07D487/04 , A61K31/551 , C07D498/04 , A61K31/5383 , C07D405/14 , C07D519/00 , C07D498/14 , C07D513/04 , A61K31/554 , A61K31/55 , A61K31/549
Abstract: Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibitng HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
-
Patent Agency Ranking
公开(公告)号：US12208088B2
公开(公告)日：2025-01-28
申请号：US17204089
申请日：2021-03-17
Applicant: Genentech, Inc.
Inventor： Sushant Malhotra , Craig Stivala , BinQing Wei , Bryan K. Chan , Timothy Heffron , Michael Lainchbury , Andrew Madin , Terry Aaron Panchal , Eileen Mary Seward , Toby Blench , Matthew W. Cartwright , Elsa Amandine Dechaux , Richard Elliott , Emanuela Gancia
IPC: A61K31/437 , A61K31/444 , A61K31/496 , A61K31/4985 , A61K31/513 , A61K31/5377 , A61K45/06 , A61P35/00 , C07D471/04 , C07D471/10 , C07D471/20 , C07D487/04 , C07D487/20 , C07D491/20 , C07D519/00
Abstract: Spirocyclic 2,3-dihydro-7-azaindole compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the spirocyclic 2,3-dihydro-7-azaindole compounds.
-
公开(公告)号：US20240368170A1
公开(公告)日：2024-11-07
申请号：US18769184
申请日：2024-07-10
Applicant: Genentech, Inc.
Inventor： Sushant Malhotra , Michael Siu , Weiru Wang , BinQing Wei , Aihe Zhou , Bryan K. Chan , Lewis J. Gazzard , Timothy Heffron , Michael Lainchbury , Andrew Madin , Eileen Mary Seward , Matthew W. Cartwright , Emanuela Gancia , David Favor , Kin Chiu Fong , Andrew Good , Yonghan Hu
IPC: C07D487/04 , C07D237/28 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/14 , C07D417/04
Abstract: Cinnoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the cinnoline compounds.
-
公开(公告)号：US20170226132A1
公开(公告)日：2017-08-10
申请号：US15499662
申请日：2017-04-27
Applicant: Genentech, Inc.
Inventor： Nicholas C. Ray , Yun-Xing Cheng , Christine Edwards , Simon C. Goodacre , Wei Li , Snahel Patel , Matthew W. Cartwright , Mohammed Sajad , Po-wai Yuen , Mark E. Zak
IPC: C07D519/00 , C07D471/04
CPC classification number: C07D519/00 , C07D471/04
Abstract: Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.
-
公开(公告)号：US11566003B2
公开(公告)日：2023-01-31
申请号：US16921297
申请日：2020-07-06
Applicant: Genentech, Inc.
Inventor： Bryan Chan , Joy Drobnick , Lewis Gazzard , Timothy Heffron , Jun Liang , Sushant Malhotra , Rohan Mendonca , Naomi Rajapaksa , Craig Stivala , John Tellis , Weiru Wang , BinQing Wei , Aihe Zhou , Matthew W. Cartwright , Michael Lainchbury , Emanuela Gancia , Eileen Seward , Andrew Madin , David Favor , Kin Chiu Fong , Yonghan Hu , Andrew Good
IPC: C07D217/22 , A61K31/549 , A61P35/00 , A61K45/06 , C07D401/04 , A61K31/4725 , A61K31/506 , A61K31/501 , C07D471/04 , C07D413/04 , C07D413/14 , A61K31/5377 , C07D417/04 , A61K31/4985 , C07D401/14 , C07D487/04 , A61K31/551 , C07D498/04 , A61K31/5383 , C07D405/14 , C07D519/00 , C07D498/14 , C07D513/04 , A61K31/554 , A61K31/55 , A61K31/472 , C07D409/14 , C07D491/04 , C07D487/14
Abstract: Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
-
公开(公告)号：US20220073520A1
公开(公告)日：2022-03-10
申请号：US17213362
申请日：2021-03-26
Applicant: Genentech, Inc.
Inventor： Sushant Malhotra , Michael Siu , Weiru Wang , BinQing Wei , Aihe Zhou , Bryan K. Chan , Lewis J. Gazzard , Timothy Heffron , Michael Lainchbury , Andrew Madin , Eileen Mary Seward , Matthew W. Cartwright , Emanuela Gancia , David Favor , Kin Chiu Fong , Andrew Good , Yonghan Hu
IPC: C07D487/04 , C07D403/04 , C07D401/04 , C07D405/14 , C07D237/28 , C07D401/14 , C07D417/04
Abstract: Cinnoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the cinnoline compounds.
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.047 seconds)
